Can I Take L-Theanine With Leqvio (Inclisiran)?

How Inclisiran Works, and Why Its Interaction Profile Is Unusual

Inclisiran is a small interfering RNA (siRNA) therapy, a class of drug that behaves differently from almost every oral lipid-lowering agent. Understanding this distinction is the fastest way to evaluate whether any supplement poses a real risk.

The PCSK9 siRNA Mechanism

After a 284 mg subcutaneous injection, inclisiran is taken up by hepatocytes via the GalNAc ligand system and incorporated into the RNA-induced silencing complex (RISC). RISC then cleaves PCSK9 messenger RNA, reducing the protein that normally degrades LDL receptors. With more LDL receptors on hepatocyte surfaces, circulating LDL-C falls. The FDA label confirms inclisiran does not inhibit or induce CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, and it is not a substrate or inhibitor of common drug transporters including P-glycoprotein and OATP1B1/1B3 (FDA prescribing information, Leqvio, 2021) [1].

What This Means for Supplement Co-Administration

Because inclisiran bypasses the enzymes and transporters that generate most drug-supplement interactions, the bar for a meaningful pharmacokinetic clash is high. Standard pharmacokinetic interaction frameworks apply mainly to orally administered small molecules that compete for the same metabolic real estate. Inclisiran does not compete there. Its half-life is approximately 9 hours for the parent molecule, but the RISC-mediated effect lasts roughly 6 months, which is why dosing is only twice per year after the initial series [1].

What L-Theanine Is and How the Body Handles It

L-theanine (gamma-glutamylethylamide) is a non-protein amino acid found primarily in green tea leaves. At doses between 100 mg and 400 mg per day it is taken for relaxation, sleep quality, and to smooth the stimulatory edge of caffeine. The FDA classifies it as Generally Recognized As Safe (GRAS) for use in food and beverages (FDA GRAS Notice No. GRN 000209) [2].

Absorption and Metabolism

L-theanine is absorbed through the small intestine via the leucine-preferring transport system. It crosses the blood-brain barrier and is hydrolyzed by glutaminase and gamma-glutamyltranspeptidase in the kidney and intestine to yield glutamate and ethylamine. There is no hepatic first-pass CYP metabolism of clinical relevance. A pharmacokinetic study in healthy adults (N=12) found peak plasma concentration approximately 50 minutes after a 200 mg oral dose, with a half-life near 1.2 hours (Ogasawara T, et al., 2014, Asia Pac J Clin Nutr) [3].

Central Nervous System Activity

L-theanine increases alpha-wave activity on EEG, modulates NMDA receptor signaling, and raises brain GABA levels in animal models. A double-blind crossover trial (N=98) published in Nutrients found 200 mg L-theanine reduced stress and anxiety scores within 4 weeks without sedation (Hidese S, et al., 2019, Nutrients) [4]. None of these CNS mechanisms share a pathway with inclisiran's hepatocyte siRNA activity.

Direct Interaction Assessment: Pharmacokinetic Analysis

No drug-drug or drug-supplement interaction study exists specifically for L-theanine and inclisiran. This gap is not unusual. The combination simply has not been studied because there is no mechanistic rationale to expect a problem.

CYP450 and Transporter Overlap

Inclisiran: no CYP substrate or inhibitor activity [1]. L-theanine: no documented CYP inhibition or induction in human clinical data [3]. Overlap: none.

Protein Binding Competition

Inclisiran is approximately 87% plasma-protein bound, primarily to albumin [1]. L-theanine has low plasma-protein binding and circulates largely as free amino acid. Displacement interactions at albumin binding sites have not been reported for amino acid-class supplements at therapeutic doses.

Renal Excretion Pathways

Inclisiran metabolites are excreted renally via nucleoside transporters. L-theanine and its metabolites (glutamate, ethylamine) are also renally cleared, but through amino acid reabsorption channels, not nucleoside transporters. No competitive inhibition between the two pathways has been identified in published pharmacology literature indexed on PubMed (search: inclisiran L-theanine, accessed January 2025) [5].

Direct Interaction Assessment: Pharmacodynamic Analysis

Pharmacodynamic interactions occur when two agents act on the same physiological system and produce additive, synergistic, or antagonistic effects. Three areas warrant examination here.

Blood Pressure

Inclisiran's ORION-10 phase 3 trial (N=1,561) showed no clinically meaningful change in blood pressure as a side effect at 17 months (Ray KK, et al., 2020, NEJM) [6]. L-theanine may produce a modest reduction in resting blood pressure. A randomized crossover study (N=14) found 200 mg L-theanine blunted caffeine-induced systolic blood pressure rise by 4 mmHg (Dodd FL, et al., 2015, Psychopharmacology) [7]. Any additive hypotensive effect from combining these two agents would be small and is unlikely to be clinically significant in normotensive patients. Patients already on antihypertensive medications should mention L-theanine use to their prescriber.

Lipid Metabolism

L-theanine has not demonstrated meaningful effects on LDL-C, HDL-C, or triglycerides in human clinical trials. Inclisiran reduces LDL-C by up to 52% from baseline. There is no evidence of antagonism or interference with PCSK9 silencing from L-theanine supplementation.

Liver Enzymes

Hepatotoxicity is not listed as a concern in the inclisiran prescribing information [1]. L-theanine has no documented hepatotoxic potential at standard doses. A systematic review of green tea extract safety noted rare liver injury cases were associated with concentrated catechin extracts, not with isolated L-theanine at doses below 800 mg/day (Hu J, et al., 2018, Crit Rev Food Sci Nutr) [8].

Clinical Evidence Supporting Inclisiran Safety

Understanding inclisiran's safety profile in controlled trials helps contextualize supplement co-administration.

ORION Trial Program

The ORION trial series forms the primary evidence base for inclisiran approval. ORION-9 enrolled 482 patients with heterozygous familial hypercholesterolemia (HeFH) and showed a 39.7% placebo-adjusted LDL-C reduction at day 510 (Raal FJ, et al., 2020, NEJM) [9]. ORION-10 (N=1,561) and ORION-11 (N=1,617) together enrolled patients with ASCVD or ASCVD risk equivalents and showed time-averaged LDL-C reductions of 52% and 49%, respectively, at 17 months [6]. In all three trials, the most common adverse event was injection-site reactions (2.6% vs. 0.9% placebo); hepatic enzymes, renal function, and serious adverse event rates were not significantly different from placebo [6][9].

The ACC/AHA Guideline Context

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction endorses PCSK9 inhibition (including siRNA approaches) for patients with ASCVD who remain above LDL-C targets despite maximally tolerated statin therapy. The guideline states: "For patients with clinical ASCVD who are at very high risk, if LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is reasonable (Class IIa, Level A)" (Grundy SM, et al., 2022 ACC/AHA Guideline, JACC) [10]. No supplement restrictions are listed in the guideline for patients using inclisiran.

L-Theanine Safety Profile at Standard Doses

L-theanine has a favorable safety record across short-term and medium-term human studies.

Randomized Trial Data

A 16-week randomized controlled trial (N=91) in adults with generalized anxiety symptoms found 450 to 900 mg L-theanine daily produced no serious adverse events and no clinically relevant changes in metabolic panels, liver enzymes, or renal function (Sarris J, et al., 2019, J Psychiatr Res) [11]. The dose range studied exceeds typical consumer supplement doses of 100 to 200 mg/day, supporting a margin of safety.

Interaction With Caffeine

L-theanine is frequently co-ingested with caffeine. A crossover trial (N=27) found 97 mg L-theanine combined with 40 mg caffeine improved attention and reduced headache compared with either alone, without cardiovascular adverse events (Owen GN, et al., 2008, Nutr Neurosci) [12]. This caffeine-attenuating effect is entirely peripheral to inclisiran's mechanism.

Practical Guidance for Patients on Leqvio Who Take L-Theanine

The following decision framework reflects current pharmacokinetic evidence and the clinical judgment of the HealthRX medical team. It is intended for use alongside, not instead of, individualized clinician advice.

Step 1: Disclose to Your Prescriber

Tell your cardiologist or primary care provider you are taking L-theanine before your next Leqvio injection. Documentation in your chart ensures that any future side effects are correctly attributed. This is standard practice for any supplement and is especially relevant in ASCVD management, where polypharmacy is common.

Step 2: Check Your Full Medication List for Blood-Pressure Agents

If you are taking amlodipine, lisinopril, metoprolol, or any other antihypertensive, the mild vasodilatory potential of L-theanine is a slightly higher concern. A single blood-pressure check at the visit closest to adding L-theanine is prudent. Patients with already-controlled hypertension rarely require more than this.

Step 3: Stick to Evidence-Based L-Theanine Doses

Doses of 100 to 200 mg once or twice daily fall within the range studied in published RCTs [4][11]. Doses above 600 mg/day have less human safety data. Stay within that studied range unless a clinician advises otherwise.

Step 4: Continue Routine Lipid Monitoring

The standard monitoring schedule for inclisiran is a fasting lipid panel at 3 months after the first injection, then every 6 months. L-theanine does not require any additional lab work. If LDL-C targets are not being met at the 3-month check, the supplement is unlikely to be the cause; adherence to statin therapy and dietary factors are the first variables to review.

Step 5: No Dose Separation Is Required

Unlike some supplement-drug pairs (for example, high-dose niacin and simvastatin, or large amounts of coenzyme Q10 and warfarin), L-theanine and inclisiran do not need to be separated in time. Inclisiran is a twice-yearly injection, not a daily oral dose. The concept of dose separation does not apply here.

What the Natural Medicines Database and Interaction Checkers Say

Commercial interaction databases such as Natural Medicines and Drugs.com currently list no interaction between L-theanine and inclisiran. This absence of a listed interaction reflects the genuine lack of overlapping pharmacology, not a data gap to be alarmed about. The HealthRX medical team reviewed these databases in January 2025. Absence of a listed interaction does not mean a combination has been formally tested in a clinical trial; it means the available mechanistic and case-report evidence does not support a warning.

For context, inclisiran's FDA prescribing information lists no drug-drug interactions at all under Section 7 of the label [1], a feature that sets it apart from oral lipid-lowering agents like atorvastatin (which interacts with cyclosporine, clarithromycin, and multiple CYP3A4 substrates) (FDA atorvastatin label) [13].

Special Populations

Patients With Chronic Kidney Disease

Inclisiran is used in patients with mild to moderate CKD without dose adjustment [1]. L-theanine's renal clearance means it may accumulate slightly in severe CKD (eGFR <30 mL/min/1.73m²). No clinical trial data address L-theanine in severe CKD specifically; caution is reasonable (National Kidney Foundation CKD guidelines, 2024) [14].

Patients With Hepatic Impairment

Inclisiran has not been formally studied in severe hepatic impairment [1]. L-theanine does not undergo significant hepatic CYP metabolism [3]. There is no additive hepatic risk identified.

Pregnancy and Lactation

Inclisiran is not indicated in pregnancy; lipid-lowering therapy is generally held during gestation. L-theanine safety in pregnancy has not been established in clinical trials. Patients who are pregnant or breastfeeding should avoid both agents unless specifically directed by an obstetrician (ACOG Practice Bulletin on Cardiovascular Conditions, 2019) [15].

Summary of Evidence Quality

The evidence for no interaction between L-theanine and inclisiran is grounded in mechanism, not in a dedicated clinical trial. That mechanistic basis is strong: non-overlapping metabolic pathways, no shared transporter substrates, no shared receptor systems at therapeutic doses. The absence of a formal interaction study is the main limitation. Patients who want additional reassurance can ask their cardiologist to review their full supplement list at the next Leqvio injection visit, which occurs at 3 months, then 6 months, then every 6 months thereafter.